$8.78
3.30% today
Nasdaq, Apr 04, 08:40 pm CET
ISIN
US10501L1061
Symbol
BWAY

Brainsway Ltd Sponsored ADR Stock price

$9.08
-0.26 2.73% 1M
-0.52 5.42% 6M
-0.35 3.71% YTD
+3.46 61.57% 1Y
+0.31 3.53% 3Y
+1.68 22.70% 5Y
-1.92 17.45% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.41 4.32%
ISIN
US10501L1061
Symbol
BWAY
Sector

Key metrics

Market capitalization $171.33m
P/E (TTM) P/E ratio 55.91
P/S ratio (TTM) P/S ratio 4.18
P/B ratio (TTM) P/B ratio 3.44
Revenue growth (TTM) Revenue growth 29.04%
Revenue (TTM) Revenue $41.02m
EBIT (operating result TTM) EBIT $1.39m
Free Cash Flow (TTM) Free Cash Flow $6.51m
Cash position $69.62m
EPS (TTM) EPS $0.16
P/S forward 3.44
Short interest 0.92%
Show more

Is Brainsway Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Brainsway Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:

Buy
100%

Financial data from Brainsway Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
41 41
29% 29%
100%
- Direct Costs 10 10
26% 26%
25%
31 31
30% 30%
75%
- Selling and Administrative Expenses 20 20
1% 1%
49%
- Research and Development Expense 7.19 7.19
8% 8%
18%
3.09 3.09
185% 185%
8%
- Depreciation and Amortization 1.70 1.70
27% 27%
4%
EBIT (Operating Income) EBIT 1.39 1.39
128% 128%
3%
Net Profit 2.92 2.92
170% 170%
7%

In millions USD.

Don't miss a Thing! We will send you all news about Brainsway Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Brainsway Ltd Sponsored ADR Stock News

Neutral
Seeking Alpha
24 days ago
BrainsWay Ltd. (NASDAQ:BWAY ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer Jeffrey S.
Neutral
GlobeNewsWire
24 days ago
Achieved r ecord quarterly s ales of $11.4 million in Q4 2024 , an increase of 27% compared with Q4 2023
Neutral
GlobeNewsWire
4 months ago
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company's Deep Transcrania...
More Brainsway Ltd Sponsored ADR News

Company Profile

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Hadar Levy
Founded 2006
Website www.brainsway.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today